Patents by Inventor Christine Collin-Djangone

Christine Collin-Djangone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11530384
    Abstract: The invention relates to the use of matrix cells for obtaining a micro hair follicle and to the use thereof for evaluating the effect of cosmetic, pharmaceutical or dermatological products and also for the prophylactic or therapeutic treatment of a state of reduced pilosity.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: December 20, 2022
    Assignee: L'OREAL
    Inventors: Khalid Bakkar, Christine Collin-Djangone
  • Publication number: 20180258390
    Abstract: The invention relates to the use of matrix cells for obtaining a micro hair follicle and to the use thereof for evaluating the effect of cosmetic, pharmaceutical or dermatological products and also for the prophylactic or therapeutic treatment of a state of reduced pilosity.
    Type: Application
    Filed: September 28, 2016
    Publication date: September 13, 2018
    Inventors: Khalid BAKKAR, Christine COLLIN-DJANGONE
  • Patent number: 9139850
    Abstract: The present invention relates to vectorization of double stranded RNA oligonucleotides by cationic particles chosen from among surfactant micelles, block or non-block polymer micelles, cationic liposomes and niosomes, cationic oleosomes and cationic nanoemulsions, as well as from among cationic organic or inorganic particles and nanocapsules, and topical compositions for the skin, mucous membranes or eyes.
    Type: Grant
    Filed: May 19, 2006
    Date of Patent: September 22, 2015
    Assignee: L'OREAL
    Inventors: Christine Collin-Djangone, Jean-Thierry Simonnet
  • Patent number: 9095630
    Abstract: The present invention relates to vectorization of double stranded RNA oligonucleotides by cationic particles chosen from among surfactant micelles, block or non-block polymer micelles, cationic liposomes and niosomes, cationic oleosomes and cationic nanoemulsions, as well as from among cationic organic or inorganic particles and nanocapsules, and to the use of compositions comprising the association of at least one dsRNA and at least one cationic particle on skin models.
    Type: Grant
    Filed: May 19, 2006
    Date of Patent: August 4, 2015
    Assignee: L'OREAL
    Inventors: Christine Collin-Djangone, Jean-Thierry Simonnet
  • Patent number: 9012418
    Abstract: Expression of a messenger RNA which encodes a protein which is expressed by differentiated cells, notably the cells of the skin or appendages thereof, is inhibited by topically administering to said differentiated cells a thus effective amount of at least one double-stranded RNA oligonucleotide, formulated into a topically applicable, physiologically acceptable medium therefor; such regime or regimen is useful for treating a variety of afflictions or conditions, e.g., combating the signs of skin aging, stimulating hair growth or retarding loss thereof, inhibiting cellular proliferation and/or differentiation, etc.
    Type: Grant
    Filed: January 9, 2008
    Date of Patent: April 21, 2015
    Assignee: L'Oreal
    Inventors: Albert Duranton, Christine Collin-Djangone, Francis Pruche, Jean-Thierry Simonnet
  • Patent number: 8822428
    Abstract: Novel double-stranded RNA oligonucleotides are useful for decreasing tyrosinase expression, have cosmetic and/or pharmaceutical applications, for example are useful skin depigmenting or anti-browning agents, and can be associated with cationic particles less than or equal to 1 ?m in size, having a zeta potential of from 10 to 80 mV.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: September 2, 2014
    Assignee: L'Oreal
    Inventors: Christine Collin-Djangone, Jean-Thierry Simmonet
  • Patent number: 8410260
    Abstract: Novel double-stranded RNA oligonucleotides are useful for decreasing tyrosinase expression, have cosmetic and/or pharmaceutical applications, for example are useful skin depigmenting or anti-browning agents, and can be associated with cationic particles less than or equal to 1 ?m in size, having a zeta potential of from 10 to 80 mV.
    Type: Grant
    Filed: October 15, 2008
    Date of Patent: April 2, 2013
    Assignee: L'Oreal
    Inventors: Christine Collin-Djangone, Jean-Thierry Simonnet
  • Publication number: 20090117063
    Abstract: Expression of a messenger RNA which encodes a protein which is expressed by differentiated cells, notably the cells of the skin or appendages thereof, is inhibited by topically administering to said differentiated cells a thus effective amount of at least one double-stranded RNA oligonucleotide, formulated into a topically applicable, physiologically acceptable medium therefor; such regime or regimen is useful for treating a variety of afflictions or conditions, e.g., combating the signs of skin aging, stimulating hair growth or retarding loss thereof, inhibiting cellular proliferation and/or differentiation, etc.
    Type: Application
    Filed: January 9, 2008
    Publication date: May 7, 2009
    Inventors: Albert Duranton, Christine Collin-Djangone, Francis Pruche, Jean-Thierry Simonnet
  • Publication number: 20090081263
    Abstract: Novel double-stranded RNA oligonucleotides are useful for decreasing tyrosinase expression, have cosmetic and/or pharmaceutical applications, for example are useful skin depigmenting or anti-browning agents, and can be associated with cationic particles less than or equal to 1 ?m in size, having a zeta potential of from 10 to 80 mV.
    Type: Application
    Filed: October 15, 2008
    Publication date: March 26, 2009
    Applicant: L'Oreal
    Inventors: Christine Collin-Djangone, Jean-Thierry Simonnet
  • Publication number: 20070134188
    Abstract: Novel double-stranded RNA oligonucleotides are useful for decreasing tyrosinase expression, have cosmetic and/or pharmaceutical applications, for example are useful skin depigmenting or anti-browning agents, and can be associated with cationic particles less than or equal to 1 ?m in size, having a zeta potential of from 10 to 80 mV.
    Type: Application
    Filed: September 21, 2006
    Publication date: June 14, 2007
    Applicant: L'OREAL
    Inventors: Christine Collin-Djangone, Jean-Thierry Simonnet
  • Publication number: 20070003501
    Abstract: The present invention relates to vectorization of double stranded RNA oligonucleotides by cationic particles chosen from among surfactant micelles, block or non-block polymer micelles, cationic liposomes and niosomes, cationic oleosomes and cationic nanoemulsions, as well as from among cationic organic or inorganic particles and nanocapsules, and to the use of compositions comprising the association of at least one dsRNA and at least one cationic particle on skin models.
    Type: Application
    Filed: May 19, 2006
    Publication date: January 4, 2007
    Applicant: L'OREAL
    Inventors: Christine Collin-Djangone, Jean-Thierry Simonnet
  • Publication number: 20070003609
    Abstract: The present invention relates to vectorization of double stranded RNA oligonucleotides by cationic particles chosen from among surfactant micelles, block or non-block polymer micelles, cationic liposomes and niosomes, cationic oleosomes and cationic nanoemulsions, as well as from among cationic organic or inorganic particles and nanocapsules, and topical compositions for the skin, mucous membranes or eyes.
    Type: Application
    Filed: May 19, 2006
    Publication date: January 4, 2007
    Applicant: L'OREAL
    Inventors: Christine Collin-Djangone, Jean-Thierry Simonnet
  • Publication number: 20050222071
    Abstract: Expression of a messenger RNA which encodes a protein which is expressed by differentiated cells, notably the cells of the skin or appendages thereof, is inhibited by topically administering to said differentiated cells a thus effective amount of at least one double-stranded RNA oligonucleotide, formulated into a topically applicable, physiologically acceptable medium therefor; such regime or regimen is useful for treating a variety of afflictions or conditions, e.g., combating the signs of skin aging, stimulating hair growth or retarding loss thereof, inhibiting cellular proliferation and/or differentiation, etc.
    Type: Application
    Filed: December 2, 2004
    Publication date: October 6, 2005
    Applicant: L'OREAL
    Inventors: Albert Duranton, Christine Collin-Djangone, Francis Pruche, Jean-Thierry Simonnet